Skip to main content

Advertisement

SpringerLink
Log in

Systemic immune inflammation index is a promising non-invasive marker for the prognosis of the patients with localized renal cell carcinoma

  • Urology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Purpose

Our aim was to evaluate the prognostic implications of a preoperative novel index, systemic immune inflammation index (SII) in patients undergoing surgery due to renal cell carcinoma.

Methods

A retrospective analysis of 176 patients who underwent radical nephrectomy and diagnosed with RCC was carried out. Systemic immune inflammation index, which is calculated by neutrophil x platelet/lymphocyte, and other inflammation indexes such as neutrophil/lymphocyte ratio, platelet/lymphocyte were included. The Kaplan–Meier analysis was plotted, and the groups were compared using a log-rank test. The ROC curve for the aforementioned inflammation indexes was plotted.

Results

SII (× 109/l) for lower and higher T stage group were 743.70 ± 587.55 and 907.06 ± 631.96, respectively, which is statistically significant (p = 0.01). Patients with higher Fuhrman grade (G3 and G4) were found to have higher SII (p = 0.001). SII 830 was demonstrated as the best cut-off value for overall survival. The optimal cut-off point for SII was defined as 850 for disease-specific survival. High SII scores were associated with poor overall survival in RCC patients (p = 0.034). However, no significant association was found for disease-specific survival (p = 0.29).

Conclusions

Systemic immune inflammation index was found to be associated with increased TNM stage and poor prognosis of RCC patients udergoing radical nephrectomy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Data availability

All datasets used and analysed during the current study are available from the corresponding author on reasonable request.

References

  1. B. Ljungberg (2019) Renal cell carcinoma- epidemıology, aetıology and pathology. EAU-Guidelines-2019. https://uroweb.org/guideline/renal-cell-carcinoma/#3.

  2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49:1374–1403

    Article  CAS  Google Scholar 

  3. Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W, Zhang X, Wang WM, Qiu SJ, Zhou J, Fan J (2014) Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res 20:6212–6222

    Article  CAS  Google Scholar 

  4. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539–545

    Article  CAS  Google Scholar 

  5. Mantovani A, Allavena P, Sica A et al (2008) Cancer-related inflammation. Nature 454:436–444

    Article  CAS  Google Scholar 

  6. Wang W, Ma X, Shi Z et al (2014) Epidermal growth factor receptor pathway polymorphisms and the prognosis of hepatocellular carcinoma. Am J Cancer Res 5:396–410

    PubMed  PubMed Central  Google Scholar 

  7. Li X, Han Z, Cheng Z, Yu J, Liu S, Yu X, Liang P (2014) Preoperative neutrophil-to-lymphocyte ratio is a predictor of recurrence following thermal ablation for recurrent hepatocellular carcinoma: a retrospective analysis. PLoS ONE. https://doi.org/10.1371/journal.pone.0110546

    Article  PubMed  PubMed Central  Google Scholar 

  8. Kolaczkowska E, Kubes P (2013) Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol 13:159–175

    Article  CAS  Google Scholar 

  9. Labelle M, Begum S, Hynes RO (2011) Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20:576–590

    Article  CAS  Google Scholar 

  10. Schumacher D, Strilic B, Sivaraj KK, Wettschureck N, Offermanns S (2013) Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell 24:130–137

    Article  CAS  Google Scholar 

  11. Ferrone C, Dranoff G (2010) Dual roles for immunity in gastrointestinal cancers. J Clin Oncol 28:4045–4051

    Article  CAS  Google Scholar 

  12. Fukuda H, Takagi T, Kondo T, Shimizu S, Tanabe K (2018) Predictive value of inflammation-based prognostic scores in patients with metastatic renal cell carcinoma treated with cytoreductive nephrectomy. Oncotarget 9:14296–14305

    Article  Google Scholar 

  13. Zhang X, Hu D, Lin X, Zhang H, Xia Y, Lin J, Zheng X, Peng F, Jie J, Niu W (2019) Prognostic value of an inflammation-related index in 6,865 Chinese patients with postoperative digestive tract cancers: the FIESTA study. Front Oncol. https://doi.org/10.3389/fonc.2019.00427.eCollection

    Article  PubMed  PubMed Central  Google Scholar 

  14. Tong YS, Tan J, Zhou XL et al (2017) Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer. J Transl Med. https://doi.org/10.1186/s12967-017-1326-1

    Article  PubMed  PubMed Central  Google Scholar 

  15. Templeton AJ, Knox JJ, Lin X et al (2016) Change in neutrophil-to-lymphocyte ratio in response to targeted therapy for metastatic renal cell carcinoma as a prognosticator and biomarker of efficacy. Eur Urol 70:358–364

    Article  Google Scholar 

  16. Hirahara T, Arigami T, Yanagita S, Matsushita D, Uchikado Y, Kita Y, Mori S, Sasaki K, Omoto I, Kurahara H, Maemura K, Okubo K, Uenosono Y, Ishigami S, Natsugoe S (2019) Combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer. BMC Cancer. https://doi.org/10.1186/s12885-019-5903-y

    Article  PubMed  PubMed Central  Google Scholar 

  17. Nakamura N, Kinami S, Fujii Y, Miura S, Fujita J, Kaida D, Tomita Y, Miyata T, Fujita H, Ueda N, Iida Y, Kosaka T (2019) The neutrophil/lymphocyte ratio as a predictor of peritoneal metastasis during staging laparoscopy for advanced gastric cancer: a retrospective cohort analysis. World J Surg Oncol. https://doi.org/10.1186/s12957-019-1651-3

    Article  PubMed  PubMed Central  Google Scholar 

  18. Ma M, Yu N, Wu B (2019) High systemic immune-inflammation index represents an unfavorable prognosis of malignant pleural mesothelioma. Cancer Manag Res 11:3973–3979

    Article  CAS  Google Scholar 

  19. Zhao LY, Yang DD, Ma XK, Liu MM, Wu DH, Zhang XP, Ruan DY, Lin JX, Wen JY, Chen J, Lin Q, Dong M, Qi JJ, Hu PS, Zeng ZL, Chen ZH, Wu XY (2019) The Prognostic Value of aspartate aminotransferase to lymphocyte ratio and systemic immune-inflammation index for overall survival of hepatocellular carcinoma patients treated with palliative treatments. J Cancer 10:2299–2311

    Article  CAS  Google Scholar 

  20. Jomrich G, Gruber ES, Winkler D, Hollenstein M, Gnant M, Sahora K, Schindl M (2019) Systemic Immune-inflammation index (SII) predicts poor survival in pancreatic cancer patients undergoing resection. J Gastrointest Surg. https://doi.org/10.1007/s11605-019-04187-z

    Article  PubMed  PubMed Central  Google Scholar 

  21. Chen L, Kong X, Wang Z, Wang X, Fang Y, Wang J (2020) Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy. J Cell Mol Med. https://doi.org/10.1111/jcmm.14934

    Article  PubMed  PubMed Central  Google Scholar 

  22. Li X, Hu P, Liu J, Zhang J, Liu Q (2020) Systemic immune-inflammation index predicted overall survival and radiosensitivity in advanced non-small-cell lung cancer. Future Oncol 16:103–115

    Article  CAS  Google Scholar 

  23. Wang B, Huang Y, Lin T (2020) Prognostic impact of elevated pre-treatment systemic immune-inflammation index (SII) in hepatocellular carcinoma: a meta-analysis. Med (Baltim). https://doi.org/10.1097/MD.0000000000018571

    Article  Google Scholar 

  24. Berardi R, Santoni M, Rinaldi S, Bower M, Tiberi M, Morgese F, Caramanti M, Savini A, Ferrini C, Torniai M, Fiordoliva I, Newsom-Davis T (2019) Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer. Ann Transl Med. https://doi.org/10.21037/atm.2019.09.18

    Article  PubMed  PubMed Central  Google Scholar 

  25. Lolli C, Basso U, Derosa L et al (2016) Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Oncotarget 7:54564–54571

    Article  Google Scholar 

  26. Chrom P, Zolnierek J, Bodnar L, Stec R, Szczylik C (2019) External validation of the systemic immune-inflammation index as a prognostic factor in metastatic renal cell carcinoma and its implementation within the international metastatic renal cell carcinoma database consortium model. Int J Clin Oncol 24:526–532

    Article  Google Scholar 

Download references

Acknowledgements

No research support or funding was received in connection with this study. The authors have no significant affiliation or involvement, either direct or indirect, with any organization or entity with a direct financial interest in the subject matter or materials discussed.

Funding

No funding.

Author information

Authors and Affiliations

  1. Department of Urology, Istanbul University Cerrahpasa Medicine Faculty, Istanbul, Turkey

    Emin Ozbek

  2. Department of Urology, Catalca Ilyas Cokay State Hospital, Istanbul, Turkey

    Huseyin Besiroglu

  3. Department of Urology, Katip Celebi University, Ataturk Training and Research Hospital, Izmir, Turkey

    Kutan Ozer, Mustafa Ozan Horsanali & Sacit Nuri Gorgel

Authors
  1. Emin Ozbek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Huseyin Besiroglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kutan Ozer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mustafa Ozan Horsanali
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sacit Nuri Gorgel
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

EO, HB, and KO were involved in the design of the study. MOH, SNG, and KO performed data acquisition. HB, and EO were involved in the statistical analysis and interpretation of data. HB, KO, and MOH wrote the draft manuscript. EO and SNG helped with the manuscript editing. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Huseyin Besiroglu.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest.

Ethics approval

The study was approved by the Katip Celebi University, Ataturk Training and Research Hospital Ethics Committee.

Informed consent

Informed consent was obtained from all subjects and the study was performed inaccordance with the Declaration of Helsinki.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ozbek, E., Besiroglu, H., Ozer, K. et al. Systemic immune inflammation index is a promising non-invasive marker for the prognosis of the patients with localized renal cell carcinoma. Int Urol Nephrol 52, 1455–1463 (2020). https://doi.org/10.1007/s11255-020-02440-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-020-02440-y

Keywords

Search

Navigation